ATE277068T1 - 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind - Google Patents

2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind

Info

Publication number: ATE277068T1
Authority: AT; Austria
Prior art keywords: rns; conformally; restricted; action; modified oligonucleotides
Prior art date: 1998-07-27

Application number

AT99935814T

Other languages

English (en)

Inventor

Muthiah Manoharan

Venkatraman Mohan

Herb Boswell

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-27

Filing date

1999-07-21

Publication date

2004-10-15

1999-07-21 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2004-10-15 Application granted granted Critical

2004-10-15 Publication of ATE277068T1 publication Critical patent/ATE277068T1/de

Links

JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 3
239000002777 nucleoside Substances 0.000 abstract 2
125000003835 nucleoside group Chemical group 0.000 abstract 2
108091034117 Oligonucleotide Proteins 0.000 abstract 1
238000000302 molecular modelling Methods 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT99935814T 1998-07-27 1999-07-21 2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind ATE277068T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/123,108 US6271358B1 (en)	1998-07-27	1998-07-27	RNA targeted 2′-modified oligonucleotides that are conformationally preorganized
PCT/US1999/016541 WO2000006590A1 (en)	1998-07-27	1999-07-21	Rna targeted 2'-modified oligonucleotides that are conformationally preorganized

Publications (1)

Publication Number	Publication Date
ATE277068T1 true ATE277068T1 (de)	2004-10-15

Family

ID=22406758

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99935814T ATE277068T1 (de)	1998-07-27	1999-07-21	2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind

Country Status (6)

Country	Link
US (1)	US6271358B1 (de)
EP (1)	EP1100809B1 (de)
AT (1)	ATE277068T1 (de)
AU (1)	AU5121399A (de)
DE (1)	DE69920477D1 (de)
WO (1)	WO2000006590A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6824976B1 (en)	1993-04-02	2004-11-30	Rigel Pharmaceuticals, Inc.	Method for selective inactivation of viral replication
US6639061B1 (en)	1999-07-07	2003-10-28	Isis Pharmaceuticals, Inc.	C3′-methylene hydrogen phosphonate oligomers and related compounds
US7812149B2 (en)	1996-06-06	2010-10-12	Isis Pharmaceuticals, Inc.	2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US6576752B1 (en) *	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6326478B1 (en)	1998-07-08	2001-12-04	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
US6277967B1 (en)	1998-07-14	2001-08-21	Isis Pharmaceuticals, Inc.	Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
DE19956568A1 (de) *	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6465628B1 (en) *	1999-02-04	2002-10-15	Isis Pharmaceuticals, Inc.	Process for the synthesis of oligomeric compounds
US20040082774A1 (en) *	1999-03-16	2004-04-29	Guzaev Andrei P.	Novel phosphate and thiophosphate protecting groups
US6121437A (en) *	1999-03-16	2000-09-19	Isis Pharmaceuticals, Inc.	Phosphate and thiophosphate protecting groups
US6610842B1 (en) *	1999-05-06	2003-08-26	Isis Pharmaceuticals, Inc.	Processes for the synthesis of oligomers using phosphoramidite compositions
US6656730B1 (en)	1999-06-15	2003-12-02	Isis Pharmaceuticals, Inc.	Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en) *	1999-07-07	2003-07-15	Isis Pharmaceuticals, Inc.	Guanidinium functionalized nucleotides and precursors thereof
US6617442B1 (en) *	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
DE10100586C1 (de) *	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
US7767802B2 (en) *	2001-01-09	2010-08-03	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) *	2001-01-09	2008-09-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7169916B2 (en) *	2002-04-01	2007-01-30	Isis Pharmaceuticals, Inc.	Chloral-free DCA in oligonucleotide synthesis
US9150605B2 (en) *	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
AU2003291755A1 (en)	2002-11-05	2004-06-07	Isis Pharmaceuticals, Inc.	Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
US9150606B2 (en)	2002-11-05	2015-10-06	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7002006B2 (en) *	2003-02-12	2006-02-21	Isis Pharmaceuticals, Inc.	Protection of nucleosides
WO2004108081A2 (en)	2003-06-02	2004-12-16	Isis Pharmaceuticals, Inc.	Oligonucleotide synthesis with alternative solvents
JP4579911B2 (ja)	2003-06-03	2010-11-10	アイシス・ファーマシューティカルズ・インコーポレイテッド	スルビビン発現の調節
AU2004263830B2 (en)	2003-06-13	2008-12-18	Alnylam Pharmaceuticals, Inc.	Double-stranded ribonucleic acid with increased effectiveness in an organism
US8969314B2 (en)	2003-07-31	2015-03-03	Regulus Therapeutics, Inc.	Methods for use in modulating miR-122a
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
KR101147147B1 (ko) *	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
JP2007531794A (ja)	2004-04-05	2007-11-08	アルニラムファーマスーティカルズインコーポレイテッド	オリゴヌクレオチドの合成および精製に使用する方法および反応試薬
AU2005323437B2 (en)	2004-04-30	2011-10-06	Alnylam Pharmaceuticals, Inc.	Oligonucleotides comprising a C5-modified pyrimidine
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7427675B2 (en) *	2004-08-23	2008-09-23	Isis Pharmaceuticals, Inc.	Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
US20060166234A1 (en)	2004-11-22	2006-07-27	Barbara Robertson	Apparatus and system having dry control gene silencing compositions
EP1931780B1 (de)	2005-08-29	2016-01-06	Regulus Therapeutics Inc.	Antisense-verbindungen mit verbesserter anti-mikrorna-aktivität
JP5111385B2 (ja) *	2005-10-28	2013-01-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	ハンチンチン遺伝子の発現を抑制するための組成物および方法
CA2626584A1 (en) *	2005-11-04	2007-05-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of nav1.8 gene
US20100069461A1 (en)	2005-11-09	2010-03-18	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of factor v leiden mutant gene
AU2007211082B2 (en)	2006-01-27	2012-09-27	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of microRNAs
AU2007299705B2 (en)	2006-09-22	2012-09-06	Dharmacon, Inc.	Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
CA2715289C (en)	2008-02-11	2019-12-24	Rxi Pharmaceuticals Corporation	Modified rnai polynucleotides and uses thereof
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
EP2274423A2 (de) *	2008-04-04	2011-01-19	Isis Pharmaceuticals, Inc.	Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
EP2313505A2 (de) *	2008-07-15	2011-04-27	F. Hoffmann-La Roche AG	Zusammensetzungen und verfahren zur expressionshemmung von tgf-beta-rezeptorgenen
US8815818B2 (en)	2008-07-18	2014-08-26	Rxi Pharmaceuticals Corporation	Phagocytic cell delivery of RNAI
EP2342340A1 (de) *	2008-09-22	2011-07-13	Rxi Pharmaceuticals Corporation	Rna-interferenz bei hautindikationen
EP2447274B1 (de)	2008-10-24	2017-10-04	Ionis Pharmaceuticals, Inc.	Oligomerverbindungen und Verfahren
WO2010055041A1 (en) *	2008-11-17	2010-05-20	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of factor vii genes
WO2010059226A2 (en)	2008-11-19	2010-05-27	Rxi Pharmaceuticals Corporation	Inhibition of map4k4 through rnai
WO2010078536A1 (en)	2009-01-05	2010-07-08	Rxi Pharmaceuticals Corporation	Inhibition of pcsk9 through rnai
AU2010211133A1 (en)	2009-02-03	2011-07-21	F. Hoffmann-La Roche Ag	Compositions and methods for inhibiting expression of PTP1B genes
US9745574B2 (en)	2009-02-04	2017-08-29	Rxi Pharmaceuticals Corporation	RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
US20120021515A1 (en)	2009-02-06	2012-01-26	Swayze Eric E	Oligomeric compounds and methods
JP2012526533A (ja) *	2009-05-15	2012-11-01	エフ．ホフマン−ラロシュアーゲー	グルココルチコイドレセプター（ｇｃｒ）遺伝子の発現を阻害するための組成物及び方法
AR078921A1 (es) *	2009-11-09	2011-12-14	Hoffmann La Roche	Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
US20110152349A1 (en) *	2009-12-18	2011-06-23	Anke Geick	Compositions and methods for inhibiting expression of il-18 genes
US20110196016A1 (en) *	2010-02-05	2011-08-11	Anke Geick	Compositions and Methods for Inhibiting Expression of IKK2 Genes
RU2615143C2 (ru)	2010-03-24	2017-04-04	Адвирна	Самодоставляющие PHKi соединения уменьшенного размера
EP3560503B1 (de)	2010-03-24	2021-11-17	Phio Pharmaceuticals Corp.	Rna-interferenz bei dermalen und fibrotischen erkrankungen
CN103200945B (zh)	2010-03-24	2016-07-06	雷克西制药公司	眼部症候中的rna干扰
EP3434772A3 (de)	2010-10-18	2019-03-20	Arrowhead Pharmaceuticals, Inc.	Zusammensetzungen und verfahren zur hemmung der expression von rrm2-genen
EA024762B9 (ru)	2011-06-30	2017-04-28	Эрроухэд Рисерч Корпорейшн	Композиции и способы ингибирования экспрессии генов вируса гепатита в
EP3052464B1 (de)	2013-10-04	2020-04-15	Novartis AG	3 endkappen für rnai-mittel zur verwendung in der rna-interferenz
WO2015051366A2 (en)	2013-10-04	2015-04-09	Novartis Ag	Novel formats for organic compounds for use in rna interference
HK1221912A1 (zh)	2013-10-04	2017-06-16	Novartis Ag	用於治疗乙肝病毒的有机化合物
CN106061488B (zh)	2013-12-02	2021-04-09	菲奥医药公司	癌症的免疫治疗
WO2015168108A2 (en)	2014-04-28	2015-11-05	Rxi Pharmaceuticals Corporation	Methods for treating cancer using nucleic targeting mdm2 or mycn
TW201620526A (zh)	2014-06-17	2016-06-16	愛羅海德研究公司	用於抑制α－１抗胰蛋白酶基因表現之組合物及方法
US10900039B2 (en)	2014-09-05	2021-01-26	Phio Pharmaceuticals Corp.	Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
EP3862005A1 (de)	2015-07-06	2021-08-11	Phio Pharmaceuticals Corp.	Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle
US10808247B2 (en)	2015-07-06	2020-10-20	Phio Pharmaceuticals Corp.	Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
AU2016306275A1 (en)	2015-08-07	2018-02-08	Arrowhead Pharmaceuticals, Inc.	RNAi therapy for Hepatitis B virus infection
WO2017070151A1 (en)	2015-10-19	2017-04-27	Rxi Pharmaceuticals Corporation	Reduced size self-delivering nucleic acid compounds targeting long non-coding rna
KR20190031306A (ko)	2016-07-21	2019-03-25	맥스시티 인코포레이티드	게놈 dna를 변경하기 위한 방법 및 조성물
JOP20190015A1 (ar)	2016-08-04	2019-02-04	Arrowhead Pharmaceuticals Inc	عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
CN110268060B (zh)	2017-01-10	2024-07-26	箭头药业股份有限公司	α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法
US12544344B2 (en)	2017-04-19	2026-02-10	Phio Pharmaceuticals Corp.	Topical delivery of nucleic acid compounds
MX2020011570A (es)	2018-05-07	2020-11-24	Alnylam Pharmaceuticals Inc	Administracion extrahepatica.
MX2021015003A (es)	2019-06-06	2022-01-24	Arrowhead Pharmaceuticals Inc	Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd).
CA3143679A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai
KR20220042116A (ko)	2019-06-18	2022-04-04	얀센 사이언시즈 아일랜드 언리미티드 컴퍼니	B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합
CN116606336B (zh) *	2022-04-02	2025-09-12	思合基因(北京)生物科技有限公司	高稳定性和亲和力的2′-o-取代核苷及其应用
WO2023233290A1 (en)	2022-05-31	2023-12-07	Janssen Sciences Ireland Unlimited Company	Rnai agents targeting pd-l1
WO2024097674A2 (en) *	2022-11-02	2024-05-10	Aligos Therapeutics, Inc.	Modified short interfering nucleic acid (sina) molecules and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
GB8607265D0 (en) *	1986-03-24	1986-04-30	London King S College	Protecting groups of organic synthesis
US5216141A (en)	1988-06-06	1993-06-01	Benner Steven A	Oligonucleotide analogs containing sulfur linkages
WO1990003881A1 (en) *	1988-10-10	1990-04-19	G.D. Engineering Pty. Limited	Pre-stretching wrapping film
US5109126A (en) *	1988-12-06	1992-04-28	Worcester Foundation For Experimental Biology	5'[2'(3')-O-(2,4,6-trinitrophenyl) pyprimidine nucleoside]diphosphate 1-glycosides
US5212295A (en)	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US6369209B1 (en) *	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5438130A (en) *	1993-01-15	1995-08-01	Cambridge Neuroscience, Inc.	Fucosylated guanosine disulfates as excitatory amino acid antagonists
US5858988A (en) *	1993-02-24	1999-01-12	Wang; Jui H.	Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US5496546A (en) *	1993-02-24	1996-03-05	Jui H. Wang	Compositions and methods of application of reactive antiviral polyadenylic acid derivatives

1998
- 1998-07-27 US US09/123,108 patent/US6271358B1/en not_active Expired - Lifetime
1999
- 1999-07-21 AT AT99935814T patent/ATE277068T1/de not_active IP Right Cessation
- 1999-07-21 WO PCT/US1999/016541 patent/WO2000006590A1/en not_active Ceased
- 1999-07-21 DE DE69920477T patent/DE69920477D1/de not_active Expired - Lifetime
- 1999-07-21 AU AU51213/99A patent/AU5121399A/en not_active Abandoned
- 1999-07-21 EP EP99935814A patent/EP1100809B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69920477D1 (de)	2004-10-28
AU5121399A (en)	2000-02-21
EP1100809B1 (de)	2004-09-22
EP1100809A4 (de)	2002-02-27
WO2000006590A1 (en)	2000-02-10
US6271358B1 (en)	2001-08-07
EP1100809A1 (de)	2001-05-23

Legal Events

Date	Code	Title	Description
2005-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE277068T1 (de)	2004-10-15	2'-modifizierte oligonucleotide mit rns wirkung, die konformell eingeschränkt sind
DE69806003D1 (de)	2002-07-18	Dna polymerasen, die verbesserte fähigkeiten zum einbau markierter nukleotide besitzen
EP1102787A4 (de)	2001-09-19	2'-o-aminoethyloxyethyl-modifizierte oligonukleotide
ATE154029T1 (de)	1997-06-15	7-deazapurin modifizierte oligonukleotide
CA2153898A1 (en)	1994-07-21	Method for generating single-stranded dna molecules
DK1178999T3 (da)	2007-08-06	L-RIBO-LNA-analoger
DE69838449D1 (de)	2007-10-31	Aminooxy-modifizierte oligonukleotide
ATE225369T1 (de)	2002-10-15	Doppelsträngige peptidenukleinsäuren
CA2167361A1 (en)	1996-07-19	2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
FI880131A7 (fi)	1988-07-15	T7-dna-polymeras.
WO2001047944A3 (en)	2003-02-20	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
BR9401355A (pt)	1994-10-18	Oligonucleotídeo e nucleotídeo.
WO1996006949A3 (en)	1996-05-09	Nucleic acid hybridization assay probes targeted to mycoplasma pneumoniae nucleic acid
BR9808730B1 (pt)	2009-01-13	processo de preparação de 1,1,1,3,3-pentaclorobutano.
WO2000029623A3 (en)	2001-04-19	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
EP1023310A4 (de)	2001-05-16	Synthese von sulfurierten oligonukleotiden
DE69936774D1 (de)	2007-09-20	Strukturproteine des virus, welches die pankreas-krankheit bei fischen verursacht, und ihre verwendungen
EP1019092A4 (de)	2004-12-15	Therapeutische und diagnostische mittel für krankheiten mit gestörter glukose-toleranz
WO2001040521A3 (en)	2002-05-16	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DE69726276D1 (de)	2003-12-24	In situ herstellung von nukleosid-phosphoramiditen und ihre verwendung in der oligonukleotidsynthese
WO2001051670A3 (en)	2002-02-28	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2000029622A3 (en)	2002-04-25	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
MX9800339A (es)	1998-09-30	Preparacion in situ de nucleosido fosforamiditas y sintesis de oligonucleotido.
WO2001038586A3 (en)	2002-04-25	Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
DK0970030T3 (da)	2003-08-04	Fremgangsmåde til at oprense 1,3,5-triisopropylbenzen